Form 4: United Therapeutics Exec Trades Shares

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving common stock, including option exercises and sales under a 10b5-1 plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, engaged in several transactions on May 19, 2026.
• These transactions included the exercise of stock options and the subsequent sale of common stock.
• A total of 9,500 shares were acquired through option exercise at a price of $146.03 per share.
• Following these transactions, Rothblatt's beneficial ownership of common stock stands at 40,513 shares directly held.
• Additional shares are held indirectly through a spouse (166 shares) and various trusts (324,443, 258,117, 45,596, and 10,962 shares).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the exercise of options is positive, the significant sale of shares by a top executive warrants attention but is mitigated by the use of a 10b5-1 plan.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a structured and compliant approach to stock sales.
• The exercise of stock options suggests that the options were in-the-money, potentially reflecting positive performance or stock value appreciation.

Negatives

• Significant sales of common stock by a key executive could be interpreted negatively by the market, potentially signaling a lack of confidence or a need for personal liquidity.

Risks

• The filing does not explicitly mention any new risks or challenges.
• However, the sale of a substantial number of shares by a high-ranking executive could be perceived as a negative signal by investors, potentially impacting share price.

Future Outlook

The 10b5-1 plan is set to continue until the earlier of the exercise of 1,734,410 stock options or December 31, 2026. The options expire on March 17, 2027.

Management Comments

• The exercise of stock options and sale of resulting shares was pursuant to a pre-arranged 10b5-1 trading plan adopted on November 7, 2025.
• The reporting person undertakes to provide full information regarding the number of shares and prices at which transactions were effected upon request.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a 10b5-1 plan by a CEO is a common strategy to diversify holdings or manage personal finances while adhering to insider trading regulations.

Stakeholder Impact

• Shareholders may view the sale of shares by the CEO with caution, potentially impacting short-term stock sentiment.
• Employees holding stock options may be encouraged by the exercise of options, indicating potential value realization.

Next Steps

• The 10b5-1 trading plan will continue until its predetermined end date or option exercise limit is reached.
• Further transactions by Martine A. Rothblatt may be reported on subsequent Form 4 filings.

Key Dates

Keywords

Form 4, SEC Filing, United Therapeutics, UTHR, Stock Options, Insider Trading, 10b5-1 Plan, Martine Rothblatt, Beneficial Ownership, Common Stock